Generic drugmaker Actavis Inc, formerly known as Watson Pharmaceuticals, reported an adjusted quarterly profit that beat market estimates, helped by new products, and the company raised its earnings forecast for the full year. Actavis posted a net loss of $102.8 million, or 79 cents per share, for the first quarter, hit by charges related to the acquisition of Actavis Group and Uteron Pharma. It had net income of $54.8 million, or 43 cents per share, a year earlier.
Actavis Inc., formerly Watson Pharmaceuticals, Inc. Shares of ACT remained unchanged at $104.39. In the past year, the shares have traded as low as $66.99 and as high as $99.55. On average, 1110020 shares of ACT exchange hands on a given day and today's volume is recorded at 0.
Source
